Renalytix plc (RNLXY)
About Renalytix plc
RENALYTIX PLC SP/ADR
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $2.3M
- Net income
- -$33.5M
- Total assets
- $8.0M
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Renalytix plc (RNLXY) Stock Price
- Reported a net loss of $33.5M in FY2024.
- Trading 74% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Renalytix plc.
Write a review
News about Renalytix plc
News & sentiment via Polygon.io
Renalytix plc: frequently asked questions
Is Renalytix plc an American company?
Renalytix plc is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Renalytix plc publicly traded?
Yes — Renalytix plc is a publicly traded company. Its stock trades under the ticker symbol RNLXY on the OTC.
What does Renalytix plc do?
Renalytix plc is an American Medical Devices company in the Health & Beauty sector.
